Yangzijiang into the $1 billion schizophrenic market.

Pharmaceutical Network June 22nd, June 18, CDE official website shows that Yangzijiang hydrochloric acid lulasiketone tablets 4 types of imitation listing application was acceptedThe application for import of ralasketone hydrochloride was approved on January 24, 2019 for the treatment of adult schizophreniaMinne data show that earlier domestic declaration of generic listing of pharmaceutical companies including Haizheng, Haussen, Zhengda Qing, currently no enterprises approved.Figure 1: The declaration of lurazone tablets of YangzijiangSource: CDE official website
Lurazisterone is an atypical (second generation) antipsychotic drug developed by Sumitomo Pharmaceuticals, for dopamine D2, 5-HT2A and 5-HT7 receptor antagonistsSince the drug was first approved by the FDA in October 2010, it has been approved for two indications, adult schizophrenia and bipolar disorder depressive episodesAccording to the data, global sales of original research products in 2018 were 184.5 billion yen ($1.716 billion).Figure 2: Earlier domestic hydrochloric acid Lulasiketone imitation listing declarationSource: Minnet net one-click search-meter net data show that the current domestic hydrochloric acid Lulasiketone tablet listing applications are 4 types of imitation, of which Haizheng Pharmaceuticals, Haussen is currently in the review and approval, Zhengda Tianqing in June to be accepted, Yangzijiang for the fourth declaration ofenterprises.Source: Company Announcements, Minnet Database
Review Data as of June 19, 2020.